Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) announced that it has been recognized in the 2022 TSX Venture 50 for top-performing stocks, and ranked in the top three for the Life Sciences sector.
The 2022 TSX Venture 50 winners were selected based on year-over-year performance across three equally weighted criteria— market capitalization growth, share price appreciation, and trading volume for the year ended December 31, 2021.
Therma Bright joins 49 other top performing TSX Venture companies across five sectors in this honor.
READ: Therma Bright says it received patent for device for applying a topical treatment from USPTO
"Therma Bright is honored to be placed in the TSX Venture 50 for top-performing stocks and ranked third in the Life Sciences category," said Rob Fia, CEO of Therma Bright in a statement.
He added: "With a solid 2022 outlook on our growing progressive diagnostic and medical device business, which includes our smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test that is moving through the US Food & Drug Administration's Emergency Use Authorization (EUA) process, our reseller partnership with DME Authority for our Venowave, Deep Vein Thrombosis Device, and our recent US patent for our TherOZap and InterceptCS technology, we're poised to not only transform innovation into wellness, but also transform these wellness solutions into profits."
Therma Bright is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges.
The company's initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare.
Contact Ritika at ritika@proactiveinvestors.com